MetaCap

Akari Therapeutics (AKTX) vs Atossa Therapeutics (ATOS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Akari Therapeutics (AKTX) has outperformed Atossa Therapeutics (ATOS) over the past year, losing 60.1% versus a loss of 86.4%. Over five years, ATOS leads with a -95.3% price change compared with -99.5% for AKTX. Akari Therapeutics is the larger company by market cap ($16.7 million vs $15.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AKTX-60.11%ATOS-86.37%
+28%-32%-92%
Nov 21, 20251 yearNov 20, 2026
AKTX-99.41%ATOS-95.48%
+16%-45%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AKTX versus ATOS key metrics
MetricAKTXATOS
Share price$7.18$1.60
Market cap$16.70M$15.92M
1-day change+7.00%-8.86%
YTD return-37.89%-81.98%
1-year return-60.11%-86.37%
5-year return-99.47%-95.34%
EPS (TTM)$0.00$-3.92
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-17.30M$-34.77M
52-week high$29.32$14.85
52-week low$3.02$1.59
Distance from 52-week high-75.51%-89.26%
Analyst consensusnonestrong_buy
Avg. price target upside+255.15%+1091.22%
Average volume58.54K68.00K
Shares outstanding2.33M9.98M
Employees516
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AKTX has outperformed ATOS by 26.3 percentage points over the past year.

About Akari Therapeutics

AKTX stock →

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About Atossa Therapeutics

ATOS stock →

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

AKTX vs ATOS FAQ

Which is bigger, Akari Therapeutics or Atossa Therapeutics?

Akari Therapeutics (AKTX) is larger, with a market capitalization of $16.70M compared with $15.92M for Atossa Therapeutics (ATOS).

Which stock has performed better over the past year, AKTX or ATOS?

AKTX returned -60.11% over the past 12 months, compared with -86.37% for ATOS (price return, excluding dividends). Past performance does not predict future results.

Are Akari Therapeutics and Atossa Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons